2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Material disclosure
Annual Report to Security Holders
Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial TM Technology Platform
Senti Holdings Issues $10 Million in Senior Secured Convertible Notes
Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Enters $40 Million Securities Purchase Agreement
Other Events
Financial Results, Press Release
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Notice of Suspension of Duty to File Reports
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
PREM14A
Post-Effective Amendment to Registration Statement
S-8 POS